After getting hopes up, expectations on Gilead, Arcus’ CD73 ‘dimmed’ on new update

When you’ve got an alliance as hefty as the one Arcus and Gilead have, every update counts. That’s why the companies found analysts frowning on the latest disclosure around quemliclustat, their small molecule inhibitor of CD73. Although an interim analysis from a triplet combo trial in pancreatic cancer looks “promising,”…

...

Click to view original post